According to results from the
pivotal Phase II
ERIVANCE BCC trial, up to 2,000 individuals
suffering from advanced basal cell carcinoma (aBCC) in the UK
could significantly benefit from a once a day pill
called vismodegib... Credit -
http://www.medicalnewstoday.com/articles/246410.php
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন